TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14530727
Drug: Delayed resection
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed resection after chemotherapy
Study: 14530727
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by resection
Study: 10720081
Drug: GHRH (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH (100 microg) plus arginine (30 g)
Study: 9121089
Drug: betapressin (penbutolol)
DrugBank: Penbutolol (DB01359)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: betapressin (penbutolol) 40 mg
Study: 9121089
Drug: betapressin at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: betapressin at a mean daily dose 108.4 +/- 6.25 mg
Study: 3965820
Drug: Cardioplegic solution
Normalized name: cardioplegic solution no.2
DrugBank: Magnesium chloride (DB09407)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cardioplegic solution infused via the aortic root
Study: 3965820
Drug: Reinfusions of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reinfusions of cardioplegic solution given both centrally and through the completed distal left anterior descending anastomosis
Study: 27555901
Drug: Locator implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Locator implant attachment
Study: 24975729
Drug: Intracoronary injection
Normalized name: HELIUM 992 mL in 1 L INTRACORONARY GAS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary injection with bone marrow mesenchymal stem cells (BMSCs) after PCI
Study: 19996066
Drug: Treatment to
Normalized name: Lice Treatment Topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment to an average systolic blood pressure of 135 to 145 mm Hg and an average diastolic blood pressure of 60 to 90 mm Hg
Study: 9726382
Drug: Olsalazine sodium,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olsalazine sodium, 3 g/day
Study: 9726382
Drug: Mesalazine, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mesalazine, 3 g/day
Study: 14719987
Drug: Chemotherapy followed
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Chemotherapy followed by radiotherapy
Study: 2564233
Drug: MC903 cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: MC903 cream (1.2 mg MC903 per g cream)
Study: 28944714
Drug: Placebo lozenge
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo lozenge
Study: 31044491
Drug: Low-dose factor
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose factor VIII (FVIII) tertiary prophylaxis, 10 IU/kg body weight, two times per week
Study: 31044491
Drug: Low-dose factor
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose factor VIII (FVIII) tertiary prophylaxis
Study: 24589084
Drug: On-demand treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: On-demand treatment
Study: 25474552
Drug: Heparinized saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparinized saline (10 U ml(-1))
Study: 10852440
Drug: Alendronate (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alendronate (10 mg daily) after PTH treatment
Study: 10852440
Drug: PTH (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTH (highest dose)
Study: 2895577
Drug: Betaxolol 10
Normalized name: betaxolol 10 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betaxolol 10 to 40 mg
Study: 2895577
Drug: Atenolol 25
Normalized name: atenolol 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atenolol 25 to 100 mg
Study: 24097273
Drug: Tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.2 mg daily for 4 weeks followed by Tamsulosin 0.2 mg and Solifenacin 5.0 mg daily for 8 weeks (Group 1)
Study: 24097273
Drug: Tamsulosin 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamsulosin 0.2 mg and Solifenacin 5.0 mg combination for 12 weeks (Group 2)
Study: 17298965
Drug: 6 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g/day propionyl‐L‐carnitine (PLC) for 7 days
Study: 9791844
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg Panax ginseng supplementation
Study: 322273
Drug: Tragant sulfate
Normalized name: SULFATE
DrugBank: Sulfate ion (DB14546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tragant sulfate (pepsin inhibitor)
Study: 31623857
Drug: DL1 (trametinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL1 (trametinib 1.5 mg, GSK2141795 50 mg)
Study: 31623857
Drug: DL-1 (trametinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: DL-1 (trametinib 1.5 mg, GSK2141795 25 mg)
Study: 27380540
Drug: Siponimod 2
Normalized name: siponimod 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Siponimod 2 mg
Study: 27380540
Drug: Siponimod 10
Normalized name: SIPONIMOD
DrugBank: Siponimod (DB12371)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Siponimod 10 mg
Study: 21432860
Drug: Azelnidipine 16
Normalized name: Azelnidipine
DrugBank: Azelnidipine (DB09230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Azelnidipine 16 mg once daily
Study: 15545306
Drug: DOV 216,303
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOV 216,303 at 150 mg (single dose)
Study: 15545306
Drug: DOV 216,303
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOV 216,303 at 100 mg (multiple doses for 10 days)
Study: 15545306
Drug: DOV 216,303
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOV 216,303 (single and multiple doses)
Study: 15545306
Drug: DOV 216,303
Approvals — FDA: no, EMA: no, PMDA: no
Description: DOV 216,303 (doses > 10 mg)
Study: 12177637
Drug: Antidepressive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressive treatment (mirtazapine, placebo-controlled); alternative treatment with citalopram if needed.
Study: 12177637
Drug: Care-as-usual (CAU);
Approvals — FDA: no, EMA: no, PMDA: no
Description: Care-as-usual (CAU); no treatment offered, psychiatric treatment outside the study recorded.
Study: 10090926
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of horse antithymocyte globulin (ATG) and cyclosporin (CSA)
Study: 8578271
Drug: Propiverine 15
Normalized name: propiverine 15 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine 15 mg/d
Study: 8578271
Drug: Propiverine 30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine 30 mg/d
Study: 8578271
Drug: Propiverine 45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine 45 mg/d
Study: 8578271
Drug: Propiverine 60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine 60 mg/d
Study: 8578271
Drug: Propiverine (15,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propiverine (15, 30, 45, 60 mg/d)
Study: 2084727
Drug: Homatropine hydrobromide
Normalized name: Homatropine Hydrobromide
DrugBank: Homatropine (DB11181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Homatropine hydrobromide (0.5% drops, two drops given twice spaced 15 minutes apart)
Study: 26519
Drug: Nadolol 40
Normalized name: nadolol 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nadolol 40 mg (20 mg twice daily) increased to a maximum of 560 mg daily
Study: 9137021
Drug: Needle injections
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Needle injections
Study: 28577267
Drug: Active music
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active music therapy (AMT)
Study: 25636304
Drug: Dextromethorphan (maximal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextromethorphan (maximal dose 90 mg/day)
Study: 23896810
Drug: More study
Normalized name: polyurethane-35 (not more than MPA.S at 40 %)
Approvals — FDA: no, EMA: no, PMDA: no
Description: More study sites, fewer university or Veterans Affairs treatment settings, lower percentage of patients assigned to receive placebo
Study: 21563510
Drug: Cognitive-behavior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavior therapy and acupoint stimulation
Study: 19304469
Drug: Ointment with
Normalized name: OINTMENT WITH APPLICATOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ointment with high dosed herbal ingredients (verum)
Study: 19304469
Drug: Placebo ointment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo ointment (control)
Study: 16409423
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg once daily continuously
Study: 16409423
Drug: Esomeprazole 20
Normalized name: esomeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole 20 mg once daily on-demand
Study: 16409423
Drug: Ranitidine 150
Normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ranitidine 150 mg twice daily continuously
Study: 15064010
Drug: Amifostine 200
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amifostine 200 mg/m2
Study: 15064010
Drug: Amifostine 340
Normalized name: Amifostine
DrugBank: Amifostine (DB01143)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amifostine 340 mg/m2
Study: 15064010
Drug: Amifostine (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amifostine (both doses)
Study: 2229525
Drug: Terbinafine 1%
Normalized name: Terbinafine 1% Topical application Gel/Jelly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbinafine 1% cream
Study: 24527444
Drug: Propofol anesthesia
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Propofol anesthesia (infusion with remifentanil)
Study: 22699673
Drug: 5% EMLA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% EMLA anesthetic cream
Study: 20357176
Drug: GnRH doses
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH doses of 0, 2.5, 10, 25, 250, and 750 ng
Study: 20357176
Drug: Transdermal testosterone
Normalized name: testosterone Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal testosterone clamp
Study: 12186515
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin K (1 mg, administered orally)
Study: 12186515
Drug: Subcutaneous vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous vitamin K (1 mg, administered subcutaneously)
Study: 10329812
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 88 micrograms twice daily
Study: 10329812
Drug: Fluticasone propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone propionate 220 micrograms twice daily
Study: 10329812
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate 168 micrograms twice daily
Study: 10329812
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate 336 micrograms twice daily
Study: 29101333
Drug: delta‐9‐THC (10 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: delta‐9‐THC (10 mg)
Study: 26611777
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion of 1500 mg of dalbavancin
Study: 26611777
Drug: 2-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose regimen of dalbavancin (1000 mg IV on day 1 followed by 500 mg IV one week later)
Study: 26611777
Drug: 2-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose regimen of dalbavancin
Study: 26611777
Drug: Single intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intravenous infusion of 1500 mg of dalbavancin in MRSA patients
Study: 26611777
Drug: 2-dose regimen
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2-dose regimen of dalbavancin in MRSA patients
Study: 22167662
Drug: Bevacizumab 5
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab 5 mg/kg with FOLFIRI
Study: 22167662
Drug: Bevacizumab 10
Normalized name: bevacizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bevacizumab 10 mg/kg with FOLFIRI
Study: 20141248
Drug: Carriers of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carriers of the DRD4-L allele
Study: 12227681
Drug: Carvedilol (25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (25-50 mg o.d. orally for 4 months)
Study: 12227681
Drug: Nifedipine (as
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nifedipine (as comparator antihypertensive drug)
Study: 3881561
Drug: Chemotherapy (CMFP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (CMFP and CMFPT groups combined)
Study: 20655559
Drug: Flomoxef 1
Normalized name: flomoxef
DrugBank: Flomoxef (DB11935)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flomoxef 1 g administered immediately before surgery
Study: 20655559
Drug: Flomoxef 1
Normalized name: flomoxef
DrugBank: Flomoxef (DB11935)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flomoxef 1 g administered twice daily for a total of 4 days from the day of surgery to postoperative day 3
Study: 18256922
Drug: GnRH agonist
Normalized name: GnRH
DrugBank: Gonadorelin (DB00644)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: GnRH agonist ovulation trigger
Study: 17166989
Drug: Montelukast, 10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast, 10 mg taken in the evening
Study: 12715418
Drug: Low calorie
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low calorie diet (1000 kcal below daily energy requirement, 1200-1500 kcal per day, 5-6 meals a day)
Study: 10766181
Drug: murine IgG2a
Normalized name: Murine Ear
Approvals — FDA: no, EMA: no, PMDA: no
Description: murine IgG2a mAb 17‐1A (500mg single infusion followed by 100mg four times every 4 weeks)
Study: 9149186
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg o.m. + Amoxicillin 1 g t.i.d. + Metronidazole 250 mg t.i.d. (first 2 weeks)
Study: 9149186
Drug: Omeprazole 40
Normalized name: omeprazole 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 40 mg o.m. + Amoxicillin 1 g t.i.d. + Metronidazole 250 mg t.i.d. (last 2 weeks)
Study: 8381089
Drug: Inhaled nedocromil
Normalized name: nedocromil Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled nedocromil sodium (Tilade)
Study: 3284943
Drug: Intravenous APSAC
Normalized name: APSAC
DrugBank: Anistreplase (DB00029)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous APSAC
Study: 3315592
Drug: Reperfused patients
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Reperfused patients (either agent)
Study: 3315592
Drug: Non-reperfused patients
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-reperfused patients (either agent)
Study: 3315592
Drug: Intracoronary streptokinase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracoronary streptokinase and intravenous APSAC
Study: 31361318
Drug: HNF1β SNP
Normalized name: SNP-ACTH (1-39)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HNF1β SNP rs752010 G > A
Study: 30053811
Drug: DENV-specific immunoglobulin
Normalized name: immunoglobulin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: DENV-specific immunoglobulin G (IgG) antibodies testing using Anti-dengue IgG ELISA
Study: 27433065
Drug: Curcumin gel
DrugBank: Curcumin sulfate (DB14635)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin gel
Study: 25126527
Drug: Triamcinolone Acetonide
Normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Triamcinolone Acetonide gel
Study: 17503877
Drug: Nutritional supplements
Normalized name: nutritional supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplements (vitamin C, vitamin E, flavonoids, L-carnitine)
Study: 17503877
Drug: Nutritional supplements
Normalized name: nutritional supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplements (various including antioxidants and amino acids)
Study: 30381282
Drug: Nutritional supplements
Normalized name: nutritional supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nutritional supplements
Study: 15857429
Drug: Topiramate (TPM)
Normalized name: Topiramate
DrugBank: Topiramate (DB00273)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Topiramate (TPM) 200 mg/day added to carbamazepine (CBZ)
Study: 12165828
Drug: 4 mg
Normalized name: lutein 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mg ondansetron (Group A, n = 29)
Study: 12165828
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg tropisetron (Group B, n = 31)
Study: 3389978
Drug: Placental albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placental albumin (1.5 g/kg)
Study: 3389978
Drug: Plasmatic albumin
Normalized name: Albumin Aggregated
DrugBank: Albumin Aggregated (DB14230)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasmatic albumin (1.5 g/kg)
Study: 31436310
Drug: Patient-controlled sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled sedation (PCS) with propofol administered by a bedside nurse anaesthetist
Study: 31436310
Drug: Midazolam sedation
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam sedation administered by the endoscopic team
Study: 24593291
Drug: Chinese five-element
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese five-element music therapy
Study: 19118825
Drug: Acupuncture (Ac)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture (Ac) during IVF treatment
Study: 16728231
Drug: Routine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine treatment (controls)
Study: 15226097
Drug: Coagulation Inhibitor
Normalized name: Protein C (coagulation inhibitor)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coagulation Inhibitor Potential (CIP)
Study: 9469625
Drug: Argatroban (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argatroban (60 mg/d for the first 2 days, then 10 mg twice daily for 5 days)
Study: 9272101
Drug: hGH at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: hGH at a weekly dosage of 0.5 IU/kg
Study: 9272101
Drug: hGH at
Normalized name: rose bengal AT
Approvals — FDA: no, EMA: no, PMDA: no
Description: hGH at a weekly dosage of 1.0 IU/kg
Study: 2658450
Drug: Combined administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined administration of 0.5 IU/kg/week hGH and a small amount of anabolic steroid
Study: 31466474
Drug: Nonsteroidal anti-inflammatory
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nonsteroidal anti-inflammatory drugs (NSAIDs) including aspirin, naproxen, diclofenac, ibuprofen, and selective cyclooxygenase 2 inhibitors such as celecoxib.
Study: 23406026
Drug: Neurostimulation plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurostimulation plus medical therapy
Study: 18842671
Drug: High bicarbonate
Normalized name: Potassium Bicarbonate
DrugBank: Potassium bicarbonate (DB11098)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High bicarbonate concentration (35 mmol/l)
Study: 18842671
Drug: High calcium
Normalized name: Nutritional Supplement Oral Liquid [ENSURE HIGH CALCIUM]
Approvals — FDA: no, EMA: no, PMDA: no
Description: High calcium concentration (1.50 mmol/l)
Study: 7999486
Drug: ephedrine 1
Normalized name: ephedrine 1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: ephedrine 1 mg min‐1 (group E1: n = 10)
Study: 7999486
Drug: ephedrine 2
Normalized name: ephedrine 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: ephedrine 2 mg min‐1 (group E2: n = 9)
Study: 7999486
Drug: phenylephrine 10
Normalized name: phenylephrine 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: phenylephrine 10 micrograms min‐1 with bolus doses of 20 micrograms
Study: 7999486
Drug: ephedrine 1
Normalized name: ephedrine 1 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: ephedrine 1 or 2 mg min‐1 with bolus doses of 6 mg
Study: 3873511
Drug: Single dose
Normalized name: Citrucel Single Dose Packets (Orange)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose trimethoprim-sulfamethoxazole
Study: 30962423
Drug: Cortisol administration
Normalized name: cortisol succinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cortisol administration after extinction training (n = 25)
Study: 30962423
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administration after extinction training (n = 25)
Study: 29197407
Drug: Low tidal
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low tidal volume (LTV) ventilation: 5 breaths/minute with a tidal volume of 3 mL/kg and positive end-expiratory pressure of 5 cmH2O
Study: 16472987
Drug: 600 mg
Normalized name: mesna 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg clindamycin
Study: 16472987
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g phenethicillin
Study: 10728957
Drug: Oral glycoprotein
Normalized name: Zaire ebolavirus envelope glycoprotein Injection [Ervebo]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral glycoprotein IIb‐IIIa inhibitor orbofiban
Study: 1539881
Drug: Buffered lidocaine
Normalized name: buffered lidocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Buffered lidocaine solutions prepared seven days, one day, and just before use
Study: 3725653
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (ampicillin and chloramphenicol)
Study: 29633302
Drug: Efavirenz tablets
Normalized name: Efavirenz Tablets
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz tablets (test product) in females
Study: 29633302
Drug: Efavirenz tablets
Normalized name: Efavirenz Tablets
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz tablets (test product) in males
Study: 29633302
Drug: Efavirenz tablets
Normalized name: Efavirenz Tablets
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz tablets (test product) in females (pivotal study)
Study: 29633302
Drug: Efavirenz tablets
Normalized name: Efavirenz Tablets
DrugBank: Efavirenz (DB00625)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Efavirenz tablets (test product) in males (pivotal study)
Study: 27847634
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (IAI) 2 mg every 8 weeks (2q8)